Metabolomics of the tumor microenvironment in pediatric acute lymphoblastic leukemia

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Tiziani, Stefano ^a,d   Kang, Yunyi ^a   Harjanto, Ricky ^a   Axelrod, Joshua ^a   Piermarocchi, Carlo ^b   Roberts, William ^c   Paternostro, Giovanni ^a  

^a BURNHAM INSTITUTE   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 OXOGLUTARIC ACID; 3 HYDROXYBUTYRIC ACID; ACETIC ACID; ACETOACETIC ACID; ACETONE; ASPARAGINASE MACROGOL; ASPARAGINE; ASPARTIC ACID; CHOLESTEROL ESTER; CHOLINE; DEXAMETHASONE; GLUCOSE; GLUTAMIC ACID; GLUTAMINE; GLYCEROL; GLYCINE; HYPOXANTHINE; LACTIC ACID; LIPID; LYSINE; METHIONINE; PALMITIC ACID; PREDNISOLONE; PREDNISONE; TRIACYLGLYCEROL; UNINDEXED DRUG; UREA; URIDINE; VALINE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; AMINO ACID BLOOD LEVEL; AMINO ACID METABOLISM; ARTICLE; BONE MARROW; CHILD; CHILDHOOD LEUKEMIA; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEROL BLOOD LEVEL; HUMAN; HUMAN TISSUE; LACTATE BLOOD LEVEL; LEUKEMIA REMISSION; LIPID METABOLISM; MALE; MASS FRAGMENTOGRAPHY; METABOLITE; METABOLOMICS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; TRIACYLGLYCEROL BLOOD LEVEL; TUMOR MICROENVIRONMENT; UREA BLOOD LEVEL;

ADOLESCENT; BONE MARROW; CHILD; CHILD, PRESCHOOL; HUMANS; INDUCTION CHEMOTHERAPY; INFANT; METABOLIC NETWORKS AND PATHWAYS; METABOLOME; METABOLOMICS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TUMOR MICROENVIRONMENT;

EID: 84892652350     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0082859     Document Type: Article

References (54)

1. Pui CH, Relling MV, Downing JR (2004) Mechanisms of disease: Acute lymphoblastic leukemia. N Engl J Med 350: 1535-1548. doi:10.1056/NEJMra023001. PubMed: 15071128.
2. Gaynon PS (2005) Childhood acute lymphoblastic leukaemia and relapse. Br J Haematol 131: 579-587. doi:10.1111/j.1365-2141.2005.05773.x. PubMed: 16351633.
3. Chen SH, Yang W, Fan Y, Stocco G, Crews KR et al. (2011) A genome-wide approach identifies that the aspartate metabolism pathway contributes to asparaginase sensitivity. Leukemia 25: 66-74. doi:10.1038/leu.2010.256. PubMed: 21072045.
4. Kawedia JD, Liu CC, Pei DQ, Cheng C, Fernandez CA et al. (2012) Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia. Blood 119: 1658-1664. doi: 10.1182/blood-2011-09-381731. PubMed: 22117041.
5. Martin Schrappe M, Hunger SP, Pui CH, Saha V, Gaynon PS et al. (2012) Outcomes after Induction Failure in Childhood Acute Lymphoblastic Leukemia. N Engl J Med 366: 1371-1381. doi:10.1056/NEJMoa1110169. PubMed: 22494120.
6. DeVita VT, Lawrence TS, Rosenberg SA (2008) DeVita, Hellman, and Rosenberg's cancer : principles & practice of oncology. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins.
7. Ayala F, Dewar R, Kieran M, Kalluri R (2009) Contribution of bone microenvironment to leukemogenesis and leukemia progression. Leukemia 23: 2233-2241. doi:10.1038/leu.2009.175. PubMed: 19727127.
8. Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR et al. (2012) Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487: 500-504. doi:10.1038/nature11183. PubMed: 22763439.
9. Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L et al. (2012) Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 487: 505-509. doi:10.1038/nature11249. PubMed: 22763448.
10. Cairns RA, Harris IS, Mak TW (2011) Regulation of cancer cell metabolism. Nat Rev Cancer 11: 85-95. doi:10.1038/nrc2981. PubMed: 21258394.
11. Glunde K, Bhujwalla ZM, Ronen SM (2011) Choline metabolism in malignant transformation. Nat Rev Cancer 11: 835-848. PubMed: 22089420.
12. Hiller K, Metallo CM (2013) Profiling metabolic networks to study cancer metabolism. Curr Opin Biotechnol 24: 60-68. doi:10.1016/j.copbio.2012.11.001. PubMed: 23206561.
13. DeBerardinis RJ, Mancuso A, Daikhin E, Nissim I, Yudkoff M et al. (2007) Beyond aerobic glycolysis: Transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci U S A 104: 19345-19350. doi: 10.1073/pnas.0709747104. PubMed: 18032601.
14. Vander Heiden MG (2011) Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Discov 10: 671-684. doi:10.1038/nrd3504. PubMed: 21878982.
15. Broome JD (1961) Evidence that the L-Asparaginase Activity of Guinea Pig Serum is responsible for its Antilymphoma Effects. Nature 191: 1114-1115. doi:10.1038/1911114a0.
16. Avramis VI, Tiwari PN (2006) Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia. Int J Nanomedicine 1: 241-254. PubMed: 17717965.
17. Panosyan EH, Grigoryan RS, Avramis IA, Seibel NL, Gaynon PS et al. (2004) Deamination of glutamine is a prerequisite for optimal asparagine deamination by asparaginases In vivo (CCG-1961). Anticancer Res 24: 1121-1125. PubMed: 15154634.
18. Avramis VI, Sencer S, Periclou AP, Sather H, Bostrom BC et al. (2002) A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood 99: 1986-1994. doi:10.1182/blood.V99.6.1986. PubMed: 11877270.
19. Richards NGJ, Kilberg MS (2006) Asparagine synthetase chemotherapy. Annual Review of Biochemistry. Palo Alto: Annual Reviews. pp. 629-654.
20. Spratlin JL, Serkova NJ, Eckhardt SG (2009) Clinical applications of metabolomics in oncology: a review. Clin Cancer Res 15: 431-440. doi: 10.1158/1078-0432.CCR-08-1059. PubMed: 19147747.
21. Asiago VM, Alvarado LZ, Shanaiah N, Gowda GAN, Owusu-Sarfo K et al. (2010) Early Detection of Recurrent Breast Cancer Using Metabolite Profiling. Cancer Res 70: 8309-8318. doi: 10.1158/0008-5472.CAN-10-1319. PubMed: 20959483.
22. Quehenberger O, Armando AM, Brown AH, Milne SB, Myers DS et al. (2010) Lipidomics reveals a remarkable diversity of lipids in human plasma. J Lipid Res 51: 3299-3305. doi:10.1194/jlr.M009449. PubMed: 20671299.
23. Serkova NJ, Standiford TJ, Stringer KA (2011) The Emerging Field of Quantitative Blood Metabolomics for Biomarker Discovery in Critical Illnesses. Am J Respir Crit Care Med 184: 647-655. doi:10.1164/rccm.201103-0474CI. PubMed: 21680948.
24. Tiziani S, Lopes V, Günther UL (2009) Early Stage Diagnosis of Oral Cancer Using 1H NMR-Based Metabolomics. Neoplasia 11: 269-U269. PubMed: 19242608.
25. Lodi A, Tiziani S, Khanim FL, Günther UL, Viant MR et al. (2013) Proton NMR-Based Metabolite Analyses of Archived Serial Paired Serum and Urine Samples from Myeloma Patients at Different Stages of Disease Activity Identifies Acetylcarnitine as a Novel Marker of Active Disease. PLOS ONE 8: e56422. PubMed: 23431376.
26. MacIntyre DA, Jiménez B, Lewintre EJ, Martín CR, Schäfer H et al. (2010) Serum metabolome analysis by (1)H-NMR reveals differences between chronic lymphocytic leukaemia molecular subgroups. Leukemia 24: 788-797. doi:10.1038/leu.2009.295. PubMed: 20090781.
27. D'Onofrio G, Zini G, Tommasi M, Laurenti L, Van Hove L et al. (1998) Automated analysis of bone marrow: Routine implementation and differences from peripheral blood. Laboratory Hematology 4: 71-79.
28. Travlos GS (2006) Normal structure, function, and histology of the bone marrow. Toxicol Pathol 34: 548-565. doi:10.1080/01926230600939856. PubMed: 17067943.
29. Tiziani S, Einwas AH, Lodi A, Ludwig C, Bunce CM et al. (2008) Optimized metabolite extraction from blood serum for 1H nuclear magnetic resonance spectroscopy. Anal Biochem 377: 16-23. doi: 10.1016/j.ab.2008.01.037. PubMed: 18312846.
30. Psychogios N, Hau DD, Peng J, Guo AC, Mandal R et al. (2011) The Human Serum Metabolome. PLOS ONE 6: e16957. PubMed: 21359215.
31. Folch J, Lees M, Sloane Stanley GH (1957) A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226: 497-509. PubMed: 13428781.
32. Ludwig C, Günther UL (2011) MetaboLab - advanced NMR data processing and analysis for metabolomics. BMC Bioinformatics 12: 366. doi:10.1186/1471- 2105-12-366. PubMed: 21914187.
33. Wishart DS, Jewison T, Guo AC, Wilson M, Knox C et al. (2013) HMDB 3.0 - The Human Metabolome Database in 2013. Nucleic Acids Res 41: D801-D807. doi:10.1093/nar/gks1065. PubMed: 23161693.
34. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate - A practical and powerful approach to multiple testing. Journal of the Royal Statistical Society Series B:-Statistical Methodology 57: 289-300.
35. Meyer PE, Lafitte F, Bontempi G (2008) minet: A R/Bioconductor package for inferring large transcriptional networks using mutual information. BMC Bioinformatics 9: 461. doi:10.1186/1471-2105-9-461. PubMed: 18959772.
36. Margolin AA, Nemenman I, Basso K, Wiggins C, Stolovitzky G et al. (2006) ARACNE: an algorithm for the reconstruction of gene regulatory networks in a mammalian cellular context. BMC Bioinformatics 7 Suppl 1: S7. doi:10.1186/1471-2105-7-S2-S7. PubMed: 16723010.
37. Basso K, Margolin AA, Stolovitzky G, Klein U, Dalla-Favera R et al. (2005) Reverse engineering of regulatory networks in human B cells. Nat Genet 37: 382-390. doi:10.1038/ng1532. PubMed: 15778709.
38. Allen JD, Xie Y, Chen M, Girard L, Xiao G (2012) Comparing statistical methods for constructing large scale gene networks. PLOS ONE 7: e29348. doi:10.1371/journal.pone.0029348. PubMed: 22272232.
39. Escherich G, Tröger A, Göbel U, Graubner U, Pekrun A et al. (2011) The long-term impact of in vitro drug sensitivity on risk stratification and treatment outcome in acute lymphoblastic leukemia of childhood (CoALL 06-97). Haematologica 96: 854-862. doi:10.3324/haematol.2010.039735. PubMed: 21330320.
40. Burstein HJ, Mangu PB, Somerfield MR, Schrag D, Samson D et al. (2011) American Society of Clinical Oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assays. J Clin Oncol 29: 3328-3330. doi:10.1200/JCO.2011.36.0354. PubMed: 21788567.
41. Waterworth PM (1978) Uniformity in sensitivity test media. J Antimicrob Chemother 4: 4-6. doi:10.1093/jac/4.1.4. PubMed: 415034.
42. Bolann BJ, Rahil-Khazen R, Henriksen H, Isrenn R, Ulvik RJ (2007) Evaluation of methods for trace-element determination with emphasis on their usability in the clinical routine laboratory. Scand J Clin Lab Invest 67: 353-366. doi:10.1080/00365510601095281. PubMed: 17558890.
43. Barnes D, Sato G (1980) Serum-free cell culture: a unifying approach. Cell 22: 649-655. doi:10.1016/0092-8674(80)90540-1. PubMed: 7460009.
44. Telang S, Lane AN, Nelson KK, Arumugam S, Chesney J (2007) The oncoprotein H-RasV12 increases mitochondrial metabolism. Mol Cancer 6: 77. doi:10.1186/1476-4598-6-77. PubMed: 18053146.
45. Hsu PP, Sabatini DM (2008) Cancer cell metabolism: Warburg and beyond. Cell 134: 703-707. doi:10.1016/j.cell.2008.08.021. PubMed: 18775299.
46. Deberardinis RJ, Sayed N, Ditsworth D, Thompson CB (2008) Brick by brick: metabolism and tumor cell growth. Curr Opin Genet Dev 18: 54-61. doi:10.1016/j.gde.2008.02.003. PubMed: 18387799.
47. Lodi A, Tiziani S, Khanim FL, Drayson MT, Günther UL et al. (2011) Hypoxia Triggers Major Metabolic Changes in AML Cells without Altering Indomethacin-Induced TCA Cycle Deregulation. ACS Chem Biol 6: 169-175. doi:10.1021/cb900300j. PubMed: 20886892.
48. Pouysségur J, Dayan F, Mazure NM (2006) Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441: 437-443. doi:10.1038/nature04871. PubMed: 16724055.
49. Butte AJ, Kohane IS (2000) Mutual information relevance networks: functional genomic clustering using pairwise entropy measurements. Pac Symp Biocomput: 418-429. PubMed: 10902190.
50. Santos CR, Schulze A (2012) Lipid metabolism in cancer. FEBS J 279: 2610-2623. doi:10.1111/j.1742-4658.2012.08644.x. PubMed: 22621751.
51. Nielsen SF, Nordestgaard BG, Bojesen SE (2012) Statin use and reduced cancer-related mortality. N Engl J Med 367: 1792-1802. doi: 10.1056/ NEJMoa1201735. PubMed: 23134381.
52. Offman MN, Krol M, Patel N, Krishnan S, Liu J et al. (2011) Rational engineering of L-asparaginase reveals importance of dual activity for cancer cell toxicity. Blood 117: 1614-1621. doi:10.1182/blood-2010-07-298422. PubMed: 21106986.
53. Grigoryan RS, Panosyan EH, Seibel NL, Gaynon PS, Avramis IA et al. (2004) Changes of amino acid serum levels in pediatric patients with higher-risk acute lymphoblastic leukemia (CCG-1961). In Vivo 18: 107-112. PubMed: 15113036.
54. Tsurusawa M, Chin M, Iwai A, Nomura K, Maeba H et al. (2004) LAsparagine depletion levels and L-asparaginase activity in plasma of children with acute lymphoblastic leukemia under asparaginase treatment. Cancer Chemother Pharmacol 53: 204-208. doi:10.1007/s00280-003-0734-5. PubMed: 14634792.